Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Nafarelin
Drug ID BADD_D01513
Description Nafarelin is a potent synthetic agonist of gonadotropin-releasing hormone with 3-(2-naphthyl)-D-alanine substitution at residue 6. Nafarelin has been used in the treatments of central precocious puberty and endometriosis.
Indications and Usage For treatment of central precocious puberty (true precocious puberty, GnRH-dependent precocious precocity, complete isosexual precocity) in children of both sexes and for the treatment of endometriosis.
Marketing Status approved
ATC Code H01CA02
DrugBank ID DB00666
KEGG ID D08241
MeSH ID D017274
PubChem ID 25077405
TTD Drug ID D08WYM
NDC Product Code Not Available
UNII 1X0094V6JV
Synonyms Nafarelin | Synarel | RS-94991-298 | RS 94991 298 | RS94991298 | Nafarelin Acetate | Nafarelin Acetate, Hydrate | Nafarelin Monoacetate
Chemical Information
Molecular Formula C66H83N17O13
CAS Registry Number 76932-56-4
SMILES CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NCC(=O)N)NC(=O)C(CC2=CC3=CC=CC=C3C=C 2)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CC5=CNC6=CC=CC=C65)NC(=O)C(CC7=CN=C N7)NC(=O)C8CCC(=O)N8
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Endometriosis21.07.01.0040.000186%Not Available
Epilepsy17.12.03.0020.000186%Not Available
Epistaxis24.07.01.005; 22.04.03.001--
Erythema nodosum23.07.02.001; 10.02.01.0200.000279%Not Available
Eye pain06.08.03.002--
Gastritis07.08.02.001--
Granulomatous liver disease09.01.07.0010.000186%Not Available
Gynaecomastia21.05.04.003; 05.05.02.003--
Headache17.14.01.001--
Hepatic function abnormal09.01.02.001--Not Available
Herpes simplex11.05.02.001; 23.11.05.004--Not Available
High density lipoprotein decreased13.12.01.003--Not Available
Hirsutism23.02.04.001; 05.05.01.005--
Hyperhidrosis08.01.03.028; 23.02.03.004--
Hypovolaemia14.05.05.002--Not Available
IIIrd nerve paralysis17.04.02.003; 06.05.02.011--Not Available
Increased appetite14.03.01.003; 08.01.09.027--Not Available
Insomnia19.02.01.002; 17.15.03.002--
Interstitial lung disease22.01.02.003; 10.02.01.033--Not Available
Libido decreased19.08.03.001; 21.03.02.005--
Libido increased21.03.02.007; 19.08.03.002--
Loss of libido19.08.03.003--Not Available
Meningioma17.20.01.005; 16.30.01.0050.000279%Not Available
Menopausal symptoms21.02.02.002--Not Available
Menopause26.03.01.001--Not Available
Menstrual disorder21.01.01.004--Not Available
Mood swings19.04.03.001--Not Available
Multiple pregnancy18.08.03.001--Not Available
Muscular weakness17.05.03.005; 15.05.06.001--
Myalgia15.05.02.001--
The 2th Page    First    Pre   2 3 4 5    Next   Last    Total 5 Pages